中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

休市中 07-10 16:08:36

5.190

+0.190

+3.80%

最高5.350	最低4.870	成交量1.77亿
今开5.050	昨收5.000	日振幅9.60%
总市值970.79亿	流通市值970.79亿	总股本187.05亿
成交额9.23亿	换手率0.95%	流通股本187.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.19,"timestamp":1783670916004,"preClose":5,"halted":0,"volume":177337052,"delay":0,"changeRate":0.038000000000000075,"floatShares":18705000000,"shares":18705000000,"eps":0.15006899476263283,"marketStatus":"休市中","change":0.19,"latestTime":"07-10 16:08:36","open":5.05,"high":5.35,"low":4.87,"amount":922826365,"amplitude":0.096,"askPrice":5.19,"askSize":639000,"bidPrice":5.18,"bidSize":811000,"shortable":3,"etf":0,"ttmEps":0.15006899476263283,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5,"dividendRate":0.019268,"openAndCloseTimeList":[[1783647000000,1783656000000],[1783659600000,1783670400000]],"volumeRatio":1.135198,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.5378,"impliedVolPercentile":0.7755},"requestUrl":"/m/hq/s/01177/tweets","defaultTab":"tweets","newsList":[{"id":"2650418688","title":"中国生物制药：IDH1抑制剂TQB3454片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2650418688","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650418688?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:04","pubTimestamp":1783674240,"startTime":"0","endTime":"0","summary":"南财智讯7月10日电，中国生物制药（01177.HK）发布自愿公告，公司附属正大天晴药业集团自主研发的国家1类创新药TQB3454片（IDH1抑制剂）新药上市申请已获中国国家药品监督管理局药品审评中心（CDE）受理，适应症为伴IDH1突变的晚期胆道癌（BTC）。该药于2023年4月被纳入CDE突破性治疗品种，2026年5月进入优先审评审批程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801887714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","IE00BZ08YR35.GBP","01177","IE00BZ08YT58.USD","BK1521","IPOS","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163842383","title":"中国生物制药（01177）自主研发IDH1抑制剂TQB3454片新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1163842383","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163842383?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:02","pubTimestamp":1783674136,"startTime":"0","endTime":"0","summary":"2026年7月10日，中国生物制药有限公司公告，其附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB3454片已向国家药品监督管理局药品审评中心递交新药上市申请并获受理，拟用于治疗伴IDH1突变的晚期胆道癌。试验对象为既往接受含吉西他滨和氟尿嘧啶类方案治疗失败且伴IDH1突变的晚期胆道癌患者。\\n\\n公告称，目前国内无同靶点药物获批用于胆道癌治疗，TQB3454如获批准，或将为IDH1突变胆道癌患者提供新的治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166743075","title":"中国生物制药TQB3454片剂获中国药监局受理 靶向IDH1突变晚期胆管癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743075","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166743075?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:59","pubTimestamp":1783673956,"startTime":"0","endTime":"0","summary":"中国生物制药（Sino Biopharmaceutical）宣布，其研发的TQB3454片剂（一种IDH1抑制剂）的新药上市申请（NDA），已获得中国国家药品监督管理局药品审评中心（CDE）受理。该药物拟用于治疗伴有IDH1突变的晚期胆管癌（BTC）患者。\n此次受理标志着该药物在向中国患者提供新的治疗选择方面迈出了关键一步。IDH1突变在多种肿瘤中存在，是潜在的治疗靶点。胆管癌是一种侵袭性强、治疗选择有限的恶性肿瘤，新药开发需求迫切。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","BK1191","01177","IE00BZ08YS42.EUR","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907869","title":"港股异动 | 中生制药(01177.HK)盘中涨近7% TQC3721海外权益以总额最高19亿美元授权给阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907869","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907869?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:33","pubTimestamp":1783665234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","HK0000165453.HKD","01177","IE00BZ08YT58.USD","BK1521","BK1191","01477","IE00BZ08YR35.GBP","BK1515","BK1589","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650098849","title":"【券商聚焦】交银国际重申中国生物制药(01177)买入评级 指下半年催化剂丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2650098849","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650098849?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:22","pubTimestamp":1783653771,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，中国生物制药 宣布：1）将公司自主研发的PDE3/4抑制剂TQC3721在中国以外地区的权益独家授予阿斯利康。公司将获得2亿美元首付款，交易总金额最高可达19亿美元，规模创下中国呼吸领域创新药单品出海的纪录。TQC3721在全球同靶点竞品中仅落后于Ohtuvayre，但已在临床研究中展示出较Ohtuvayre更广的COPD患者群体覆盖潜力及一定疗效优势。近期股价回调后，当前主业估值仅0.7倍2026年PEG，重申买入及目标价7.7港元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150492384","title":"异动解读 | 中国生物制药盘中大涨5%，阿斯利康与GSK双重利好提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150492384","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150492384?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:35","pubTimestamp":1783650915,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)今日盘中股价大涨5%，引起了市场的广泛关注。消息面上，公司近期连续宣布两笔重磅交易，显著提振了市场信心。其附属公司正大天晴药业将自主研发的PDE3/4抑制剂TQC3721的海外权益，以最高19亿美元的总对价授权给阿斯利康，其中包含2亿美元的首付款。同日，公司宣布深化与葛兰素史克(GSK)的独家战略合作，获得了全再乐及欧乐欣两款慢性阻塞性肺疾病(COPD)药物在中国内地的商业化权益。此外，高盛近日上调了公司的盈利预测，招银国际也维持了“买入”评级，认为连续的全球对外授权充分彰显了公司的内部研发创新能力，为股价提供了有力支撑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103530234","title":"异动解读｜中国生物制药盘中上涨3.2%，阿斯利康及GSK双线合作持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1103530234","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103530234?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:05","pubTimestamp":1783649120,"startTime":"0","endTime":"0","summary":"7月10日，中国生物制药盘中上涨3.2%，报5.16港元/股，成交额1.58亿港元。消息面上，公司近日连续官宣两笔重磅交易：其附属公司正大天晴药业将自主研发的PDE3/4抑制剂TQC3721海外权益以最高19亿美元总对价授权给阿斯利康，含2亿美元首付款；同日宣布深化与葛兰素史克的独家战略合作，获得全再乐及欧乐欣两款慢阻肺药物在中国内地的商业化权益。高盛近日调升公司盈测，招银国际维持\"买入\"评级，目标价8.70港元，认为连续的全球对外授权充分彰显了公司内部研发创新能力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910717","title":"中国生物制药(01177)涨近6% 近日达成两项重大合作 获高盛调升盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910717","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650910717?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:31","pubTimestamp":1783564278,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药 早盘股价持续冲高，截至发稿，报5.1港元，涨幅5.81%，成交额2.64亿港元。高盛近日研报指，中生制药近日达成两项重大合作，包括与阿斯利康达成TQC3721的独家授权协议，获其支付2亿美元首付款，以及最高17亿美元的开发、监管及商业里程碑付款，另加基于净销售额的分级特许权使用费，成为公司今年内继与赛诺菲合作后，第二宗跨国药企授权交易，进一步印证其内部研发平台具备全球竞争力。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985465","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU0942090050.USD","LU2471134879.HKD","LU0345770993.USD","LU2237443465.HKD","IE00B19Z3581.USD","BK4588","LU1791807156.HKD","LU2471134796.USD","01177","LU2237443382.USD","LU2471134952.CNY","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU1868836591.USD","LU1894683264.USD","LU0251142724.SGD","LU0096364046.USD","BK1521","LU1868836757.USD","LU2265009873.SGD","GSX","LU0061475181.USD","IE00BSNM7G36.USD","BK4552","IE00BFXG1179.USD","IE0004091025.USD","LU2471134523.USD","IE00B19Z3B42.SGD","LU0742534661.SGD","BK1589","BK4516","LU0048573561.USD","LU2237443978.SGD","IE0004086264.USD","BK4550","LU2750360641.GBP","BK4533","LU0106831901.USD","BK1191","LU1868836914.USD","IE0002270589.USD","LU1868837300.USD","LU2237438978.USD","LU0345770308.USD","LU2237443895.HKD","LU1894683348.USD","LU2750360997.AUD","HK0000165453.HKD","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910625","title":"中国生物制药早盘涨超5% 与GSK进一步深化独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910625","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650910625?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:12","pubTimestamp":1783563120,"startTime":"0","endTime":"0","summary":"　　中国生物制药早盘涨超5%，截至发稿，股价上涨5.39%，现报5.08港元，成交额2.39亿港元。　　7月8日，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克“GSK”于2026年5月达成的独家战略合作，推动两款呼吸领域重磅创新药物惠及更多中国患者。本次合作是集团与GSK战略合作的又一重要进展，标志着双方合作领域从肝病进一步拓展至呼吸系统疾病。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-09/doc-inihench4479325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","LU1829250122.USD","IE00BZ08YS42.EUR","BK4588","BK4532","01177","BK4585","IE00BZ08YR35.GBP","GSKH","BK1515","BK1589","GSK.UK","GSK","HK0000165453.HKD","IE00BZ08YT58.USD","BK4007","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166944619","title":"异动解读 | 中国生物制药盘中大涨5.19%，与阿斯利康、葛兰素史克达成重磅合作提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1166944619","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166944619?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:03","pubTimestamp":1783562601,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中股价大幅上涨5.19%，引起市场广泛关注。招银国际发布研报指出，连续的全球对外授权充分彰显了中国生物制药的内部研发创新能力，并维持其“买入”评级。与阿斯利康的合作中，公司不仅获得2亿美元首付款，后续里程碑付款及销售分成潜力巨大；而与GSK的合作进一步拓展了公司在呼吸系统疾病领域的商业化版图。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126611861","title":"异动解读｜中国生物制药盘中上涨4.15%，阿斯利康及GSK双线合作持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1126611861","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126611861?lang=zh_cn&edition=full","pubTime":"2026-07-09 09:56","pubTimestamp":1783562164,"startTime":"0","endTime":"0","summary":"7月9日，中国生物制药盘中上涨4.15%，报5.01港元/股，成交额1.43亿港元。同日，公司还宣布深化与葛兰素史克的独家战略合作，获得GSK旗下全再乐及欧乐欣两款重磅慢阻肺药物在中国内地的商业化权益，合作领域由肝病拓展至呼吸系统疾病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650917058","title":"招银国际：维持中国生物制药(01177.HK)买入评级 目标价8.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650917058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650917058?lang=zh_cn&edition=full","pubTime":"2026-07-09 09:48","pubTimestamp":1783561720,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1191","BK1521","BK1515","IE00BZ08YT58.USD","01177","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650917519","title":"港股开盘涨跌不一 恒指跌0.07% 老铺黄金(06181)跌2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650917519","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650917519?lang=zh_cn&edition=full","pubTime":"2026-07-09 09:29","pubTimestamp":1783560555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘涨跌不一，恒指跌0.07%，国企指数平开，恒生科技指数高开0.29%。截至2026年6月30日止6个月，集团的激光雷达产品约为71.92万台，其中，用于ADAS应用的激光雷达产品及用于机器人及其他的激光雷达产品的销量分别约为43.66万台及28.26万台。内地股市昨日下跌，沪综指数低开低走，收市跌0.5%，沪深两市成交额进一步减少。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985447","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880398554.USD","LU2152927971.USD","LU0593848301.USD","LU0561508036.HKD","IE00BZ08YR35.GBP","LU0211977185.USD","LU0541502299.USD","IE0032431581.USD","LU0231483743.USD","LU0359202008.SGD","SG9999001069.SGD","LU1226287529.USD","LU0072913022.USD","LU0588545904.SGD","LU1655091459.SGD","LU0543330483.HKD","LU0708995153.HKD","LU0516422440.USD","BK1528","LU1634259557.SGD","LU0477156797.USD","LU0261947096.USD","SG9999014674.SGD","LU0821914370.USD","IDRV","LU0259732245.USD","LU0572944931.SGD","LU0588546209.SGD","LU1993786604.SGD","LU1044874839.SGD","SG9999001226.SGD","LU0264606111.USD","LU1960683339.HKD","LU1568876251.USD","LU1048484197.HKD","07300","LU0577902611.USD","LU0396098781.USD","LU0274383008.USD","07552","LU0405327494.USD","LU0329678170.USD","LU0651947912.USD","LU0762542818.HKD","LU0327786744.USD","LU1282651048.USD","LU0348783662.USD","ALBmain","LU2097829019.USD","LU0149721374.USD","IE00BMPRXR70.SGD","LU0235996351.USD","LU0228367735.SGD","BK1591","LU1497733557.USD","BK1587","LU0048597586.USD","SG9999001051.SGD","80175","BK1117","LU2039709279.SGD","LU2045819591.USD","LU0577902371.SGD","IE0008368742.USD","LU0164880469.USD","LU0642271901.SGD","LU0029874905.USD","LU0096374516.USD","LU0862451837.USD","02837","SGXZ86797644.SGD","IE00BPRC5H50.USD","LU0140636845.USD","LU1226287875.USD","LU0831093199.SGD","LU0972618739.USD","LU0823413587.USD","LU0651946864.USD","LU0106259558.USD","LU0181495838.USD","BK1249","LU0348827113.USD","LU0469268626.HKD","LU0130103400.USD","WHGLY","LU2242644610.SGD","513600","03033","LU1064130708.USD","LU2360107325.USD","LU0117841782.USD","01177","LU1769817096.USD","IE00BWDBJ730.SGD","LU2357305700.SGD","LU0823038988.USD","LU0348735423.USD","LU0648000940.SGD","LU1044876610.USD","LU0164872284.USD","LU0856984785.SGD","600938","LU0791591158.USD","LU0873338254.USD","IE00B0JY6N72.USD","LU0868486357.SGD","LU1328277881.USD","LU2148510915.USD","LU1515016050.SGD","LU0164865239.USD","BK1584","IE00B5MMRT66.SGD","00981","KURE","BK1226","FDNI","LU0516422952.EUR","LI","83115","LU2328871848.SGD","SG9999001689.USD","LU1366334651.USD","LU2488822045.USD","02833","00857","LU0577902538.SGD","LU0348783233.USD","03032","LU1201861165.SGD","LU0132412106.USD","LU0210526637.USD","LU1808992512.USD","HK0000320223.HKD","LU0823397103.USD","LU1152091168.USD","LU0516422366.SGD","LU0244354667.USD","LU0106959298.USD","BK1191","LU0054450605.USD","IE00BQJZWZ67.USD","SG9999000327.SGD","LU1064131003.USD","LU1224709979.USD","BK1614","LU0823413660.USD","LU0143863784.USD","LU0329678337.USD","LU1880398471.USD","LU0229945570.USD","00883","SGXZ62798434.SGD","LU1568876335.HKD","LU0320764599.SGD","LU0054237671.USD","LU0315178854.USD","BK1238","LU1051769294.HKD","LU1481107354.HKD","89888","LU0608807433.USD","LU1282649067.USD","LU0648948544.HKD","LU0499858438.USD","LU0328353924.USD","09088","LU2476274720.SGD","LU1497734951.SGD","LU1981816686.USD","LU1166156734.SGD","LU0890818403.SGD","LU2125910849.SGD","LU1642822792.SGD","LU0634319403.HKD","LU0672654166.SGD","LU1770034418.SGD","BABA","LU0384037296.USD","LU1720051017.SGD","LU1044875133.USD","LU2293587155.HKD","03115","LU2294711473.HKD","SG9999001093.SGD","02498","LU0314109678.HKD","SGXZ90724238.SGD","LU1303224171.USD","LU0441854154.USD","LU0831103253.SGD","LU1242518931.SGD","LU0326950275.SGD","BKF","LU0540923850.HKD","LU0589944569.HKD","LU0501845795.SGD","LU1675838814.USD","LU0315179316.USD","LU1969619763.USD","LU0163747925.USD","LU0196878994.USD","LU0531970944.HKD","LU0117844026.USD","LU0320764243.SGD","LU0640798160.USD","LU0254981946.USD","BK1610","LU0572940350.SGD","02800","LU0039217434.USD","LU2097828631.EUR","BK1575","SG9999000459.SGD","09888","BK1142","LU2257852520.SGD","GELYY","LU1282649810.SGD","BK1095","03417","SG9999002950.SGD","BK1608","LU2097828714.EUR","LU0871576103.HKD","LU0541501648.USD","LU0862451753.SGD","MCHmain","BK1589","LU0702159699.USD","LU1242518857.USD","LU1366334578.USD","LU1688375341.USD","LU0737861772.HKD","LU1211504680.USD","BK1521","LU0577902454.USD","HK0000151867.HKD","LU0880133367.SGD","BK1237","LU0417516738.SGD","SG9999002828.SGD","601857","LU0823426480.USD","IE00B543WZ88.USD","LU0630378692.HKD","SG9999002463.SGD","LU1152091754.HKD","LU0823039010.USD","LU2399975544.HKD","LU0605514214.HKD","LU1224444064.USD","LDEM","LU1868837565.USD","LU0417516571.SGD","HK0000306685.HKD","HBBD.SI","IE00BMPRXN33.USD","BK1501","IE0008369823.USD","02015","LU0449515922.USD","LU1051768304.USD","HK0000286598.CNH","02513","BK1526","IE00B19Z5X02.USD","BK1119","LU0197773160.USD","LU0898667661.SGD","LU1961090484.USD","LU0287142896.SGD","LU0737861699.HKD","LU0456827905.SGD","LU0051755006.USD","00175","HK0000165453.HKD","LU0197773673.USD","LU0463099449.HKD","LU0650527681.SGD","LU0149534421.HKD","LU1316542783.SGD","BK1179","LU0127658192.USD","LU1023057109.AUD","LU0700851271.USD","LU0165289439.USD","LU0823397285.USD","HSI","LU1226288170.HKD","82800","BK1539","01093","HSTECH","06181","LU0048580855.USD","LU0084288322.USD","LU0128522744.USD","LU0455707207.USD","LU1868838027.USD","IE00B031HY20.USD","LU0431992006.USD","LU0572939691.SGD","HHImain","BK1609","SBHMY","HK0000306701.USD","LU0516423174.USD","LU1008478684.HKD","LU1831875114.USD","LU1282649141.HKD","LU1226287792.SGD","03067","LU1951186391.HKD","LU0047713382.USD","LU1328615791.USD","LU0531971595.HKD","LU0345775950.USD","BK1502","LU0210527791.USD","LU0784639295.USD","BK1586","LU0370786039.SGD","00288","LU0228659784.USD","LU0762541174.USD","LU1188198961.HKD","03423","LU2097828805.USD","LU1048596156.SGD","LU0067412154.USD","LU0214875030.USD","LU1634259391.SGD","LU1807302812.USD","SG9999002562.SGD","LU0173614495.USD","LU1719994722.HKD","09115","LU0261950983.USD","LU1522347837.USD","07500","LU0029875118.USD","09988","LU2125910500.SGD","LU1226288253.USD","SG9999001903.USD","IE0034224299.USD","LU1548497426.USD","LU0823040885.USD","BK1615","LU0130518102.USD","09903","LU0359201612.USD","LU1769817179.HKD","LU0828237510.HKD","LU0143863198.USD","IE00B0169N27.USD","LU2476274308.USD","LU0488056044.USD","SG9999004220.SGD","LU0708995583.HKD","LU0819121731.USD","LU1048588211.SGD","LU1861219969.SGD","LU2778985437.USD","03037","IE0003895053.USD","LU1770036033.HKD","BIDU","IE00BZ08YS42.EUR","LU2449936058.SGD","LU1861214812.USD","LU1794554557.SGD","LU1196710864.SGD","SG9999006597.SGD","89988","LU0611395673.USD","LU0502904849.HKD","LU0607220059.USD","BK1517","LU1956131251.USD","LU0049853897.USD","LU0405327148.USD","LU0577902298.EUR","LU0791590937.USD","LU0828237940.HKD","LU1115378108.SGD","LU0516423091.SGD","LU0348788117.USD","LU1813983027.USD","LU0345776255.USD","LU0128522157.USD","LU0307460666.USD","LU0979878070.USD","BK1607","LU0630378429.USD","LU1810669033.SGD","LU1497733631.SGD","LU0043850808.USD","LU0169518387.USD","SG9999006514.SGD","KWEB","LU0865486749.SGD","LU0011963245.USD","IE0008368304.USD","LU0417516902.SGD","SG9999003461.SGD","LU0449509016.USD","LU1720051108.HKD","LU0594300179.USD","BK1588","03419","LU0823041008.USD","688981","LU0072462343.USD","CXSE","LU1504937902.USD","LU0061477393.USD","LU0588545490.SGD","LU0823426308.USD","LU0594300419.USD","LU0762540952.USD","LU1785774172.SGD","HK0000320264.USD","LU0456846285.SGD","LU2097828557.USD","07226","BK1163","LU0588545730.USD","07200","LU1323998911.USD","LU0359201885.HKD","LU0106252389.USD","LU1282651121.HKD","LU1439103000.SGD","LU0348805143.USD","LU0348825331.USD","LU2087589342.USD","80883","HK0000107257.USD","LU0675040207.SGD","LU1880383366.USD","BK1618","LU0293314216.USD","LU2097828474.EUR","TCHI","LU0320764755.SGD","09067","LU0348784397.USD","BK1544","LU0048388663.USD","LU0543330566.HKD","BK1515","LU0886674414.USD","LU0608807946.USD","LU1251922891.USD","03088","LU0499858602.USD","BK1227","BK1543","IE00BZ08YT58.USD","LU0052750758.USD","LU1880383440.USD","BK1603","LU1720050803.USD","EVS.SI","IE00B3M56506.USD","LU0251144936.SGD","LU0819123356.HKD","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649509995","title":"中国生物制药盘中涨近7%：一天官宣两笔交易，均涉慢阻肺","url":"https://stock-news.laohu8.com/highlight/detail?id=2649509995","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649509995?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:47","pubTimestamp":1783511220,"startTime":"0","endTime":"0","summary":"7月8日，港股龙头药企中国生物制药（1177.HK）盘中最高涨近7%，最终平收，报4.82港元/股，市值901.58亿港元。消息面上，中国生物制药当天官宣两笔BD交易，一个是将在研管线授权给跨国药企，一个是拿下跨国药企成熟品种在华的权益，均涉及慢性阻塞性肺疾病（COPD）这一呼吸疾病。公开信息显示，慢阻肺是全球第三大致死原因，目前全球有5亿患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798563411.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798563411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ08YT58.USD","BK1521","01177","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969580","title":"中国生物制药分别与阿斯利康、葛兰素史克达成重要合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969580","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649969580?lang=zh_cn&edition=full","pubTime":"2026-07-08 15:55","pubTimestamp":1783497300,"startTime":"0","endTime":"0","summary":"7月8日，中国生物制药有限公司（以下简称“中国生物制药”）公告称，将自主研发的慢性阻塞性肺疾病（COPD）创新药TQC3721（PDE3/4抑制剂）海外权益以总额最高19亿美元授权给阿斯利康，创下近三年中国呼吸领域单产品交易额之最；同日，中国生物制药还宣布将进一步深化与葛兰素史克（GSK）的战略合作，获得GSK两款全球重磅呼吸创新药在中国内地的独家商业化权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798367659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","BK1515","LU2237443465.HKD","BK1191","LU0310800379.SGD","LU0320765992.SGD","LU0708994859.HKD","LU2237443382.USD","BK4588","LU2237443622.USD","LU2462157665.USD","LU2417539215.USD","GSK.UK","IE00BZ08YS42.EUR","LU2236285917.USD","IE00BZ08YR35.GBP","BK1589","LU0289739699.SGD","01177","IE00B3T34201.USD","BK4532","LU0128525929.USD","LU2237443895.HKD","LU0432979614.USD","AZNH","LU0889565916.HKD","LU0109394709.USD","IE00BZ08YT58.USD","BK4007","BK4568","LU0058720904.USD","LU1267930573.SGD","BK1521","LU2237443978.SGD","LU0029864427.USD","LU2456880835.USD","LU2237443549.SGD","AZN","LU2089984988.USD","BK4585","LU2468319806.SGD","GSKH","LU1829250122.USD","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649027952","title":"葛兰素史克与中国生物制药深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649027952","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649027952?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:14","pubTimestamp":1783484047,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1829250122.USD","IE00BZ08YS42.EUR","BK4585","BK4007","GSKH","HK0000165453.HKD","BK1521","IE00BZ08YR35.GBP","BK1191","BK1589","BK4588","BK4532","IE00BZ08YT58.USD","GSK.UK","BK1515","01177","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127955732","title":"中国生物制药将负责相关产品在中国大陆的进口、分销等业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1127955732","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127955732?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:08","pubTimestamp":1783483683,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，公司将负责特定产品在中国大陆市场的进口、分销及其他相关业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU0161305163.EUR","LU0321505439.SGD","LU1098665638.USD","IE00BQJZX424.USD","IE0034235071.USD","IE00B3T34201.USD","IE00BZ08YS42.EUR","LU0987226296.USD","LU1487256676.USD","SG9999001176.USD","BK5011","LU0557290698.USD","LU1645745479.HKD","LU2089984988.USD","LU1400636657.SGD","LU2646069778.SGD","LU1064927863.SGD","BK1589","LU0306807586.USD","LU1202635105.USD","LU2468319806.SGD","LU0225284248.USD","LU0203345920.USD","LU0321505868.SGD","LU1228905037.USD","LU1228905540.USD","BK1515","LU1309081286.SGD","BK1521","LU1481600234.SGD","HK0000165453.HKD","GSK.UK","IE00BZ08YT58.USD","LU0306806265.USD","LU0971552673.USD","LU1481599808.USD","LU0211331839.USD","LU1302929846.USD","LU1046248800.SGD","BK1191","SG9999001176.SGD","01177","LU0575583348.USD","LU0971552830.HKD","LU1670756490.USD","SG9999013999.USD","IE00BZ08YR35.GBP","SGXZ57979304.SGD","LU0225771236.USD","LU1035777561.USD","LU1400636574.HKD","LU0289739699.SGD","LU0203347892.USD","LU0058720904.USD","LU0545562505.USD","LU1983299246.USD","LU0109981661.USD","LU1400636491.USD","LU1015430645.USD","LU0985481810.HKD","IE00BWDBJ516.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105036328","title":"中国生物制药获GSK慢阻肺双药中国商业化授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1105036328","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105036328?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483577,"startTime":"0","endTime":"0","summary":"中国生物制药已成功获得葛兰素史克旗下两款重磅慢性阻塞性肺疾病治疗药物——Trelegy Ellipta与Anoro Ellipta在中国的商业化权利。此举标志着这家中国领先的医药企业在呼吸疾病领域的产品管线与市场布局得到显著强化。此项合作不仅将提升中国生物制药在呼吸系统疾病领域的核心竞争力，也反映了跨国药企与中国本土龙头企业深化战略协作，共同开拓中国巨大医疗市场的新趋势。预计该授权将为中国生物制药的未来营收增长注入新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1515","01177","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180615564","title":"中国生物制药深化与GSK在中国呼吸疗法领域的独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1180615564","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180615564?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483573,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，将进一步深化与葛兰素史克在中国市场呼吸系统治疗领域的独家战略合作伙伴关系。此举旨在整合双方优势资源，共同推进创新呼吸疗法在中国的研发、商业化及市场准入，以应对国内日益增长的呼吸疾病诊疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK1589","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1191","01177","BK1515","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649072952","title":"中国生物制药：深化与GSK呼吸领域战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649072952","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649072952?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483560,"startTime":"0","endTime":"0","summary":"【中国生物制药：深化与GSK呼吸领域战略合作】南财智讯7月8日电，中国生物制药（01177.HK）发布自愿公告，宣布其附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克（GSK）于2026年5月达成的独家战略合作，获得GSK两款呼吸领域创新药——氟替美维吸入粉雾剂（商品名：全再乐）和乌美溴铵维兰特罗吸入粉雾剂（商品名：欧乐欣）在中国内地的商业化权益，包括进口、分销、医院准入及推广活动，相关销售收入全额确认为正大天晴营业收入。本次合作系双方继肝病领域后首次拓展至呼吸系统疾病，标志本集团呼吸管线从研发向商业化全面升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","BK4532","GSK.UK","IE00BZ08YT58.USD","LU1829250122.USD","BK1191","HK0000165453.HKD","BK4585","GSK","IE00BZ08YS42.EUR","BK1515","GSKH","01177","IE00BZ08YR35.GBP","BK1521","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0949},{"period":"1month","weight":0.1666},{"period":"3month","weight":-0.1133},{"period":"6month","weight":-0.2315},{"period":"1year","weight":-0.1075},{"period":"ytd","weight":-0.1506}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0664},{"period":"6month","weight":-0.0784},{"period":"1year","weight":0.0061},{"period":"ytd","weight":-0.0568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.007657},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056403},{"month":3,"riseRate":0.565217,"avgChangeRate":0.046203},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020807},{"month":5,"riseRate":0.695652,"avgChangeRate":0.037978},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004739},{"month":7,"riseRate":0.652174,"avgChangeRate":0.05392},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010627},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.014397},{"month":10,"riseRate":0.545455,"avgChangeRate":0.024699},{"month":11,"riseRate":0.5,"avgChangeRate":0.067223},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.012172}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}